Inovio Pharmaceuticals, formerly Inovio Biomedical Corp., develops DNA-based vaccines, to treat and prevent cancers and infectious diseases.
The Cowen 32nd Annual Health Care Conference is slated to take place between March 5 and 7 at the Boston Marriott Copley Place.
Inovio's chief executive, Joseph Kim, is slated to make his presentation at the symposium on March 5, Monday, at 3:30 p.m. and will last 30 minutes.
Cowen's symposium attracts top institutional investors and leading companies ranging from consumer retail, technology to health care and aerospace and defence.
The second conference hosted by Roth Capital Partners is scheduled to take place between March 11 and 14 in California, at The Ritz Carlton.
Chief financial officer, Peter Kies, will make his presentation at the Roth 24th Annual Conference on Wednesday, March 14 at 11:30 a.m.
The Roth Capital event is designed to offer investors to gain insight into small and mid-cap companies across a number of sectors like: business services, cleantech, media and software.
A live and archived webcast of the presentation will be accessible on Inovio's website at www.inovio.com.
The company's SynCon vaccines are designed to provide broad cross-strain protection against known and newly emergent unmatched strains of pathogens such as influenza.
These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown to generate positive immune responses, along with a favourable safety profile.
Inovio's clinical programs include phase II studies for cervical dysplasia, pre-cancerous lesions, leukemia and the hepatitis C virus, as well as phase I studies for influenza and HIV.
The company's share price jumped 2.84 percent to 59.6 cents apiece in trade on the New York Stock Exchange.